hVIVO PLC
LSE:HVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (10.8), the stock would be worth GBX-9.42 (229% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8.4 | GBX7.3 |
0%
|
| 3-Year Average | 10.8 | GBX-9.42 |
-229%
|
| Industry Average | 0.5 | GBX-0.4 |
-105%
|
| Country Average | 0.2 | GBX-0.18 |
-102%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
GBX67.3m
|
/ |
Jan 2026
£-6m
|
= |
|
|
GBX67.3m
|
/ |
Dec 2026
£-3.3m
|
= |
|
|
GBX67.3m
|
/ |
Dec 2027
£-769.3k
|
= |
|
|
GBX67.3m
|
/ |
Dec 2028
£3.2m
|
= |
|
|
GBX67.3m
|
/ |
Dec 2029
£10.4m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| UK |
|
hVIVO PLC
LSE:HVO
|
50.2m GBP | -8.4 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 46.7 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 19.7 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.2 |
| 70th Percentile | 0.3 |
| Max | 828.3 |
Other Multiples
hVIVO PLC
Glance View
hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
